Pixium Vision

Pixium Vision EBITDA per Share

Delisted

The EBITDA per Share of Pixium Vision (ALPIX.PA) as of Nov 2, 2026 is -11.39 EUR. In the previous year, EBITDA per Share was -9.96 EUR — a change of 14.32% (lower).

EBITDA per Share

-11.39EUR

YoY

14.32%

Last updated:

EBITDA per Share of Pixium Vision is 2022 -11.39 EUR. EBITDA per Share of Pixium Vision was 2021 -9.96 EUR. It decreases by 14.32% lower compared to the previous year.

The Pixium Vision EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2015
-0.97 EUR
Jan 1, 2016
-0.75 EUR
Jan 1, 2017
-0.80 EUR
Jan 1, 2018
-0.27 EUR
Jan 1, 2019
-0.32 EUR
Jan 1, 2020
-10.75 EUR
Jan 1, 2021
-9.96 EUR
Jan 1, 2022
-11.39 EUR
The Pixium Vision EBITDA per Share history
YEAREBITDA per ShareYoY
-11.39EUR+14.32%
-9.96EUR-7.28%
-10.75EUR+3,231.15%
-0.32EUR+20.94%
-0.27EUR-66.68%
-0.80EUR+7.03%
-0.75EUR-22.71%
-0.97EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pixium Vision Stock analysis

What does Pixium Vision do? Pixium Vision SA develops implantable medical devices for treating blindness caused by retinal photoreceptor cell degeneration. The company focuses on two Vision Restoration Systems (VRS) platforms, IRIS and PRIMA, which electrically stimulate retinal cells to restore partial vision in patients with retinitis pigmentosa. Pixium Vision collaborates with academic institutions like Institut de la Vision, Universite Pierre et Marie Curie, Stanford University, and University of Ulm to advance its retinal implant technology. The firm generates revenue through the development and commercialization of these medical devices, targeting patients with specific retinal conditions and healthcare providers in the ophthalmology sector. Pixium Vision SA's primary products, the IRIS and PRIMA systems, are designed to restore partial vision for patients suffering from retinitis pigmentosa. The company partners with academic institutions such as the Institut de la Vision and Universite Pierre et Marie Curie to conduct research and development on retinal implants. Revenue is derived from the sale of these Vision Restoration Systems to hospitals and clinics specializing in ophthalmology, where they are used to treat patients with degenerative retinal diseases. The company's focus on developing implantable medical devices for vision restoration positions it within the medical technology sector, serving patients with specific visual impairments. The firm's Vision Restoration Systems (VRS) platforms, IRIS and PRIMA, enable patients with retinitis pigmentosa to partially recover vision through electrical stimulation of retinal cells. Pixium Vision collaborates with technology and academic institutions including Institut de la Vision, Universite Pierre et Marie Curie, Stanford University, and University of Ulm to support its R&D efforts. Revenue streams come from the commercialization of these medical devices, sold to healthcare providers in the ophthalmology field who treat patients with retinal degeneration. The company's business model centers on developing and selling implantable devices for vision restoration, targeting a niche medical market with specific patient needs. Pixium Vision is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pixium Vision stock

EBITDA per Share of Pixium Vision is -11.39 EUR in 2022.

EBITDA per Share of Pixium Vision changed from -9.96 EUR to -11.39 EUR, representing a 14.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Pixium Vision since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Pixium Vision

All Key Metrics — Pixium Vision